◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksA › ABLD

ABL Diagnostics Société anonyme (ABLD) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Health Information Services · DATA UPDATED 2026-08-16

ABL Diagnostics Société anonyme (ABLD) operates in the Health Information Services industry and is headquartered in Woippy, France with about 22 employees. Its market capitalization is roughly €39 million. In the fiscal year ended 2025-12-31, ABLD reported €7M in revenue and €1M in net income.

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally.

Interactive charts & full statements →

ABLD Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue€7M€5M€6M€9M
Gross Profit€7M€5M€5M€8M
Operating Income (EBIT)€0M(€0M)(€1M)€0M
Net Income€1M€0M€0M€1M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ABLD Free Cash Flow History

ABLD Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets€13M€12M€15M€15M
Total Liabilities€5M€4M€8M€9M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ABLD viewer.

Other Companies in Health Information Services

← ABGAll “A” companiesABLV →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.